logo

For the Inventor, By the Inventor

Osaka, Japan

Takeda Pharmaceutical Company Limited

Calculating rank
USPTO Granted Patents = 1,229

% Expired Patents = 36.2



Trademarks = 18

Forward Citations = 4,274

Loading Chart...
Loading Chart...

1,681 inventors (with patents filed for the assignee):

goldMedal Tatsuki Koike (51 out of 51 patents)

silverMedal Makoto Kamata (42 out of 43 patents)

bronzeMedal Masato Yoshikawa (39 out of 84 patents)

4.  Minoru Nakamura (36 out of 72 patents)

5.  Takahiro Sugimoto (34 out of 36 patents)

6.  Jeffrey Alan Stafford (32 out of 143 patents)

7.  Tsuneo Yasuma (31 out of 44 patents)

8.  Tsuneo Oda (30 out of 43 patents)

9.  Hiroki Sakamoto (29 out of 64 patents)

10.  Yasutaka Hoashi (29 out of 29 patents)

11.  Norihito Tokunaga (28 out of 28 patents)

12.  Takuto Kojima (28 out of 28 patents)

13.  Yasushi Hattori (26 out of 101 patents)

14.  Masami Yamada (25 out of 25 patents)

15.  Yuichi Kajita (25 out of 25 patents)


Core Competencies:
Immunoglobulin
Cationic Lipid
Gastrointestinal
Heterocyclic Compound
Therapeutic Agents
Monoclonal Antibody
Viral Inhibitors
Cryopreservation
Sickle Cell Disease
Nucleic Acids
Cancer Treatment
Biological Compositions

1,229 patents:

1. 12774450 - T cell progenitor production method (2026-10-27),
2. 12767667 - Macrocyclic heterocycle compounds and use thereof (2026-10-20),
3. 12766073 - Pooling device for single or multiple medical containers (2026-10-20),
4. 12748086 - Support fixture for chromatography columns (2026-09-29),
5. 12747273 - HTT repressors comprising a zinc-finger protein transcription factor. (2026-09-29),
6. 12742779 - KITS (2026-09-22),
7. 12741957 - N-heteroarylalkyl-2-(heterocyclyl and heterocyclylmethyl) acetamide derivatives as SSTR4 agonists (2026-09-22),
8. 12723028 - Heterocyclic compound (2026-09-01),
9. 12716084 - Heparin-insensitive assay for factor XIa (2026-08-25),
10. 12703852 - Hematopoietic progenitor cell marker (2026-08-11),
11. 12693298 - ANTI-VEDOLIZUMAB ANTIBODIES AND USES THEREOF (2026-07-28),
12. 12691037 - Medicinal fluid delivery device (2026-07-28),
13. 12673112 - CCR8 ANTIBODIES, ANTIBODY CONJUGATES, AND USES THEREOF (2026-07-07),
14. 12662453 - Heterocyclic compound and use thereof (2026-06-23),
15. 12661368 - Maribavir isomers, compositions, methods of making and methods of using (2026-06-23),
Company Overview
Takeda Pharmaceutical Company Limited, headquartered in Osaka, Japan, is a global leader in the pharmaceutical industry, focusing on innovative treatments that address unmet medical needs. The company specializes in a range of therapeutic areas, including immunology, gastrointestinal disorders, and oncology, leveraging advanced technologies such as monoclonal antibodies and viral inhibitors. Takeda is committed to enhancing patient outcomes through its research in cationic lipids and heterocyclic compounds, while also exploring novel approaches in cryopreservation.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Takeda Pharmaceutical Company Limited USPTO Patent Assignee Logo
1,229 Patents

#21 in Osaka

#193 in Japan

#833 in the World

Osaka, JP
Osaka, Japan

Takeda Pharmaceutical Company Limited

Forward Citations = 4,274

1,681 inventors:

goldMedal Tatsuki Koike (51 out of 51 patents)

silverMedal Makoto Kamata (42 out of 43 patents)

bronzeMedal Masato Yoshikawa (39 out of 84 patents)

4.  Minoru Nakamura (36 out of 72 patents)

5.  Takahiro Sugimoto (34 out of 36 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Takeda Pharmaceutical Company Limited. Retrieved from https://idiyas.com/company/takeda-pharmaceutical-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…